Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PIT565

Bispecific antibody · Immune activation, directed at CD19, CD3 (CD3E) and CD2 · developed by Novartis Pharmaceuticals

Phase 1 Most advanced trial
NVS Developer
1 Registered trials

What is PIT565?

PIT565 is an antibody that binds CD19 on tumor cells and CD3 and CD2 on T-cells, cross-linking them to trigger a cytotoxic T-lymphocyte response against CD19-expressing cells. It is being studied in B-cell non-Hodgkin lymphoma and B-cell acute lymphoblastic leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
CD19, CD3 (CD3E), CD2
Mechanism
Immune activation, directed at CD19, CD3 (CD3E) and CD2
Pathways
T-cell mediated cytotoxicity
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05397496 Phase 1 B-cell Non-Hodgkin Lymphoma (B-NHL) Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin Lymphoma (B-NHL)

Other drugs acting on CD19 / CD3E / CD2

More from Novartis Pharmaceuticals

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind PIT565

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.